The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Public ClinicalTrials.gov record NCT01707992. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod in participants with RRMS. The study has 2 periods: Period 1, the double-blind, placebo-controlled period (up to 24 months) and Period 2, the active treatment period (24 months).
Study identification
- NCT ID
- NCT01707992
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,199 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 20, 2013 (Actual)
- Primary completion
- Apr 13, 2015 (Actual)
- Completion
- Jul 4, 2017 (Actual)
- Last update posted
- Nov 9, 2021
2013 – 2017
United States locations
- U.S. sites
- 32
- U.S. states
- 16
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 10329 | Cullman | Alabama | 35058 | — |
| Teva Investigational Site 10349 | Sun City | Arizona | 85351 | — |
| Teva Investigational Site 10342 | Tucson | Arizona | 85741-3537 | — |
| Teva Investigational Site 10310 | Fresno | California | 93710 | — |
| Teva Investigational Site 10307 | Aurora | Colorado | 80045 | — |
| Teva Investigational Site 10334 | Centennial | Colorado | 80112 | — |
| Teva Investigational Site 10332 | Fort Collins | Colorado | 80528 | — |
| Teva Investigational Site 10316 | Coral Gables | Florida | 33146 | — |
| Teva Investigational Site 10308 | Sarasota | Florida | 34233 | — |
| Teva Investigational Site 10341 | St. Petersburg | Florida | 33701 | — |
| Teva Investigational Site 10315 | Sunrise | Florida | 33351 | — |
| Teva Investigational Site 10323 | Tampa | Florida | 33606 | — |
| Teva Investigational Site 10350 | Chicago | Illinois | 60612 | — |
| Teva Investigational Site 10345 | Evanston | Illinois | 60201 | — |
| Teva Investigational Site 10343 | Northbrook | Illinois | 60062 | — |
| Teva Investigational Site 10339 | Fort Wayne | Indiana | 46805 | — |
| Teva Investigational Site 10348 | Lenexa | Kansas | 66214 | — |
| Teva Investigational Site 10338 | Boston | Massachusetts | 02215 | — |
| Teva Investigational Site 10346 | Advance | North Carolina | 27006 | — |
| Teva Investigational Site 10347 | Winston-Salem | North Carolina | 27157 | — |
| Teva Investigational Site 10309 | Bellevue | Ohio | 44811 | — |
| Teva Investigational Site 10317 | Columbus | Ohio | 43221 | — |
| Teva Investigational Site 10325 | Dayton | Ohio | 45417 | — |
| Teva Investigational Site 10340 | Hershey | Pennsylvania | 17033-0850 | — |
| Teva Investigational Site 10331 | Philadelphia | Pennsylvania | 19104 | — |
| Teva Investigational Site 10313 | Cordova | Tennessee | 38018 | — |
| Teva Investigational Site 10324 | Franklin | Tennessee | 37064 | — |
| Teva Investigational Site 10318 | Nashville | Tennessee | 37205 | — |
| Teva Investigational Site 10319 | Salt Lake City | Utah | 84103 | — |
| Teva Investigational Site 10330 | Newport News | Virginia | 23601 | — |
| Teva Investigational Site 10311 | Roanoke | Virginia | 24018 | — |
| Teva Investigational Site 10335 | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 252 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01707992, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01707992 live on ClinicalTrials.gov.